Real-world study of extranodal lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how people with non-Hodgkin lymphoma that affects organs or tissues outside the lymph nodes (extranodal) respond to standard treatments in real-world settings. It may help doctors understand what works best for this type of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with non-Hodgkin lymphoma that has spread to or started in an area outside the lymph nodes (extranodal).
- You have received treatment that works throughout your body (like chemo or immunotherapy).
- You have at least one tumor or spot that can be measured on scans to track how well treatment works.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks people newly diagnosed with non-Hodgkin lymphoma to learn more about the disease and how treatments work. It helps doctors improve future care by collecting real-world data.
This study enrolls adults with Hodgkin or non-Hodgkin lymphoma who plan to receive chemotherapy aimed at cure. It may help doctors better understand outcomes and how lymphoma care is managed over time.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This study looks at why lymphoma happens and what factors affect how well people do. It collects information from patients diagnosed between 2007 and 2027 to better understand the disease.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.